



NEWS & VIEWS

JULY 2005

Advancing Scholarship in Laboratory Medicine

2	NACB'S NEW STRATEGIC PLAN
3	STRATEGIC PLAN
4	THE ACADEMY OF AACC
5	DISTINGUISHED ABSTRACT AWARDS
6	TOPIC AND SPEAKER SCHEDULE
7	MEMBERSHIP COMMITTEE REPORT



PRESIDENT'S CORNER

It's hard to believe that half the year has gone by and we are all ready to attend the XIX International Conference of Clinical Chemistry IFCC/AACC 2005 Annual Meeting

in July, only a few weeks away. The Academy will have a busy week in Orlando and we hope that you can participate in many of our activities. Most of these NACB activities will be on Wednesday July 27.

- I will be presenting the NACB Award Winners on Wednesday morning just before the Plenary session at 8:30am in the Morial Convention Center. The recipient of the NACB Distinguished Scientist Award is Leonard Jarett, MD, FACB; the recipient of the NACB Alvin Dubin Award is Charles D. Hawker, PhD, MBA, FACB; and the recipient of the NACB George Grannis Award (Young Scientist) is Jennifer A. Snyder, PhD.
- Eleftherios Diamandis and his committee have planned a superb LMPG EduTrak on "Guidelines for Use of Tumor Markers in the Clinic" for Wednesday July 27th beginning at 10:30am. The session will go from 10:30am-noon and from 2:45-5pm.
- The NACB Annual Awards Luncheon and Membership Meeting will take place on Wednesday at 12:30pm in the Peabody Hotel. I hope to see many of you there.

- We have named 25 Distinguished Abstracts for 2005 and I'd like to thank Tom Annesley and his committee for their hard work in choosing these deserving recipients. These 25 abstracts were chosen from more than 825 submitted abstracts for the meeting and truly represent the purpose of this program which is to promote the scholarship of discovery and recognize those abstracts describing exceptional studies.
- The NACB co-sponsors the AACC Student Poster Contest together with ComACC and the ABCC. This year it will be held on Monday afternoon from 2-4:30pm at the convention center. If you are free, I would like to invite all of our members to attend and support this outstanding event.

The Leadership of the Academy and AACC will continue their discussions on a closer relationship between the two organizations and plan to meet in St. Louis in August. I'll update you on the discussions and any conclusions we reach once the Board of Directors of both groups have had an opportunity to meet and discuss the issues.

Thank you again for giving me this opportunity to serve the Academy and I look forward to seeing you all in Orlando.

MARY BURRITT, PH.D., FACB
President

**NATIONAL ACADEMY OF CLINICAL BIOCHEMISTRY
OFFICERS AND BOARD OF DIRECTORS – 2005**

PRESIDENT

Mary Burritt, PhD, FACB
Mayo Clinic
Lab Med & Path
200 1st Street SW
Rochester, MN 55905-0002
507-284-3954
507-266-4176
mburritt@mayo.edu

PRESIDENT-ELECT

Thomas Annesley, PhD, FACB
University of Michigan
1500 East Medical Center Drive
University Hospital, Room 2G332
Ann Arbor, MI 48109-0054
734-936-6775
734-763-4095
annesley@umich.edu

SECRETARY

Catherine Hammett-Stabler, PhD, FACB
Univ of North Carolina Chapel Hill
Pathology and Laboratory Medicine
Campus Box 7525, Pathology
Chapel Hill, NC 27599-7525
919-966-3724
cstabler@unch.unc.edu

TREASURER

Robert M. White Sr., PhD, FACB
550 West Place
Naples, FL 34108
239-561-8208
239-561-8255
robert.white@dsilabs.com

PAST PRESIDENT

D. Robert Dufour, MD, FACB
10316 Gainsborough Rd
Potomac, MD 20854 202-745-8285
202-745-8284
d.robert.dufour@med.va.gov

NEWSLETTER EDITOR

Stanley F. Lo, PhD, FACB
Childrens Hospital of Wisconsin
Pathology & Lab Medicine
9000 West Wisconsin Avenue
Wauwatosa, WI 53226
414-266-2508
414-266-2779
slo@mail.mcw.edu

The policy of the NACB is that only the President, President-Elect, Secretary, and Treasurer may make official statements on behalf of the NACB. This limitation does not apply to the conduct of routine business transactions. All views expressed in the newsletter are solely those of the contributors, authors, or editors and not necessarily those of the NACB.

DIRECTORS

2003-2004

Carolyn Feldkamp, PhD, FACB
Henry Ford Hospital
Pathology
2799 W Grand Blvd.
Detroit, MI 48202
313-916-3172
313-916-1138
cfeldka1@hfhs.org

Ronald Whitley, PhD, FACB
University of Kentucky
Pathology & Laboratory Medicine
800 Rose Street, Room HA-615
Lexington, KY 40536
859-257-4030
859-257-8932
rjwhit00@uky.edu

2004-2006

Michael Bennett, PhD, FACB
Children's Hospital of Philadelphia
Pathology and Lab Medicine
34th & Civic Center Blvd.
Philadelphia, PA 19104-4399
215-590-3394
bennettmi@email.chop.edu

Larry Broussard, PhD, FACB
LSU Health Sciences Center
1900 Gravier Street
10th floor
New Orleans, LA 70112-2262
504-568-4281
504-568-6761
lbrous@lsuhsc.edu

2005-2007

Stephen Kahn, PhD, FACB
Loyola University Medical Center
Pathology & Cell Biology/
Laboratory Medicine
2160 South First Avenue
Room 0122, Clinical Laboratories
Maywood, IL 60153-3304
708-216-4725
708-216-1639
skahn@lumc.edu

Gerald Kost, MD, PhD, FACB
506 Citadel Drive
Davis, CA 95616
530-752-7355
530-752-4548
gjkost@ucdavis.edu

STAFF LIASON

Penelope Jones
AACC
2101 L Street, NW
Suite 202
Washington, DC 20037-1558
Phone: 202-835-8746
Fax: 202-887-5093
pjones@aacc.org

NACB's New Strategic Plan

At its spring meeting, the Board approved final revisions to the NACB's new strategic plan. The plan, which sets the priorities for the organization, was originally developed in 1998 by a committee, headed by Roland Valdes. The Board updated the plan to recognize changes in priorities, and because many of the elements in the prior plan had already been accomplished. The Board emphasized five main areas, three which were retained from the previous plan and two of which represent refocused areas of emphasis: Research, Education, Professional Development, Clinical Practice, and its role as the Academy of AACC. At the same time, the Board also reviewed our Vision and Mission. The Board reaffirmed our core membership (Doctoral Clinical Biochemists) and our joint interests with AACC (to serve as the Academy of AACC) in these two statements.

A strategic plan should not be a static document, and the Board welcomes your feedback on our vision for the future of NACB. We hope you will take the time to read through our strategic plan and take part in shaping the direction of NACB as we proceed through our second quarter-century of existence.

D. Robert Dufour, M.D., FACB
Past-President, NACB



STRATEGIC PLAN

National Academy of Clinical Biochemistry *The Academy of AACC*

This Strategic Plan will be used to guide the development of the National Academy of Clinical Biochemistry (Academy), and will be updated at intervals as needed. The purpose is to develop the Academy to meet the needs of its members and the profession. The emphasis is on enhancing the practice and profession of clinical biochemistry through the scholarships of discovery, application, integration, and education. Whenever possible, measurable outcomes will be used as indices of success.

Vision: As doctoral clinical biochemists, to be the leading scholarly organization advancing the science and practice of clinical laboratory medicine.

Mission: To advance clinical practice and research, to promote education and professional development in clinical laboratory medicine, and to serve as the Academy of AACC.

The Academy will carry out this mission by using the following five Strategic Objectives as a guide for implementing the Strategic Plan.

STRATEGIC OBJECTIVES

Strategic Objective I (Research). The Academy will be the leading advocate for scholarship through scientific research in clinical laboratory science.

- 1) Support research on outcomes data relating to laboratory tests
- 2) Recognize outstanding abstracts at the AACC Annual Meeting.
- 3) Support and recognize student research through activities such as the student poster contest and Grannis Award.
- 4) Support and recognize expertise in research, for example through the Distinguished Scientist Award.

Strategic Objective II (Education). The Academy will provide outstanding educational programs relat-

ing to the scholarships of discovery, application, and integration in clinical medicine.

- 1) Develop and support educational programs on laboratory medicine to laboratory professionals, clinicians, and other health professionals.
- 2) Develop mechanisms to distribute educational materials to the laboratory community.
- 3) Disseminate information on Laboratory Medicine Practice Guidelines through meetings, and print and electronic media.

Strategic Objective III (Professional Development).

The Academy will enhance the professional development of its members and promote the value of the profession.

- 1) Promote ABCC and certification of doctorate level clinical biochemists
- 2) Partner with other laboratory medicine professional associations to continually assess the issues and needs of the work environment.
- 3) Maintain the vitality of the Academy by active membership recruitment.
- 4) Recognize service to the Academy, for example by the Dubin Award and special commendations as determined by the Board.
- 5) Develop Academy leaders by providing opportunities to participate in Academy committees and programs.
- 6) Support and promote COMACC.

Strategic Objective IV (Clinical Practice). In collaboration with other professional and clinical organizations, the Academy will be the leading laboratory society in the development of systematic reviews and laboratory practice guidelines.

- 1) Develop Laboratory Medicine Practice Guidelines (LMPGs) in cooperation with clinical organizations, based on review of evidence and consensus of experts.
- 2) Become a leader in developing systematic reviews in laboratory medicine, partnering with clinical organization and AHRQ.
- 3) Develop information for lay people regarding evidence on laboratory tests for incorporation into LabTests Online or the NACB web site.
- 4) Develop mechanism for assuring currency of LMPGs.

Strategic Objective V (The Academy of AACC). The Academy will assume greater responsibilities within the AACC and continue to refine its roles on behalf of both the Academy and AACC.

- 1) Assume primary role for AACC in review of guidelines, developed by other organizations for endorsement.
- 2) Increase involvement of NACB representation on appropriate committees of AACC.
- 3) Serve as the scientific advisory group to the AACC.
- 4) Provide and advise on position papers/statements to AACC as needed.
- 5) Facilitate interaction between AACC and clinical professional organizations.

(Approved by the Board on April 18, 1998; Revised by the Board on March 13, 2005)

The National Academy of Clinical Biochemistry The Academy of AACC

The National Academy of Clinical Biochemistry is the Academy of AACC and is dedicated to advancing the science and practice of clinical laboratory medicine through research, education, and professional development. The Academy is a leading advocate for scholarship through scientific research and it conducts educational programs to promote scientific discovery, application, and integration. It publishes laboratory medicine practice guidelines for the application of clinical biochemistry to medical diagnosis and therapy. NACB will conduct the following activities at the AACC Annual Meeting:

Monday, July 25

1:30 – 3:00 pm

NACB Board of Directors Meeting
Peabody Hotel

Wednesday, July 27

10:30am-12noon/2:45-5pm

NACB Guidelines for Use of Tumor Markers
in the Clinic

Edutrak 3401

Orange County Convention Center, Orlando, FL

Wednesday, July 27

12:30-2:15pm

NACB Awards Luncheon and Membership Meeting
Peabody Hotel

Luncheon cost: \$25.00

Make reservations in advance using the AACC Annual Meeting registration form.

NACB members are invited to attend this luncheon in honor of new Academy Fellows and recipients of the following awards:

Leonard Jarrett, MD, FACB

Distinguished Scientist Award

Sponsored by Dade Behring Inc.

Charles D. Hawker, PhD, MBA, FACB

Professor Alvin Dubin Award for Distinguished Contributions to the Discipline of Clinical Biochemistry

Sponsored by Abbott Diagnostics

Jennifer A. Snyder, PhD

George Grannis Award for Outstanding Scientific or Clinical Report

(Given in recognition of outstanding achievements by young investigators)

Sponsored by NACB with support from the Ohio Valley Section of AACC

Tuesday-Thursday, July 26-28

NACB Exhibit

Orange County Convention Center, Orlando, FL

Learn more about NACB membership and Laboratory Medicine Practice Guidelines (LMPG) publications during the AACC Clinical Lab Exposition.

NACB membership is open to AACC members who are doctoral level clinical scientists, hold ABCC certification or have at least 10 years of postdoctoral experience in clinical biochemistry, and are active in research, education, or service to the field. For an NACB membership application, go to the NACB web site at www.nacb.org or contact Penelope Jones at AACC (pjones@aacc.org or call 202-659-8370.)

National Academy of Clinical Biochemistry Distinguished Abstract Awards

The NACB is proud to announce the following recipients of its 2005 Distinguished Abstract Awards. This Academy program is designed to promote the scholarship of discovery and recognize scientific excellence among abstracts accepted for presentation at the XIX International Congress of Clinical Chemistry IFCC/AACC 2005 Meeting. The following 25 abstracts were chosen from 837 abstracts accepted for presentation at the meeting.

A rigorous selection process is used that incorporates a primary review by AACC members followed by a second review performed by a group of NACB Fellows. Only those abstracts that meet strict criteria during both reviews are designated as Distinguished Abstracts.

Tuesday, July 26, 10:00 a.m. A-108

Anissa Djemli, PhD

**Cystatin C: A Marker of Kidney Function
in Pediatric Oncology.**

Tuesday, July 26, 10:00 a.m. A-140

David W. Seccombe, MD, PhD

**Standardization of Creatinine: a Pre-requisite
for Implementing the MDRD Formula for the
Estimation of Glomerular Filtration Rate (eGFR)**

Tuesday, July 26, 10:00 a.m. A-145

Raffick A. Bowen, PhD

**Investigation of Immunoassay Interference
from Reformulated Blood Collection Tubes.**

Tuesday, July 26, 2:00 p.m. B-13

Maninder Kaur

**Diagnostic and Prognostic Value of Serum
Glycoproteins (Sialic Acid and Hexosamines)
in Breast Cancer.**

Tuesday, July 26, 2:00 p.m. B-19

Bernard C. Cook, PhD

**The Use of the Prostate Specific Antigen (PSA)
Isoforms, BPH-A and ProPSA, to Improve the
Specificity of PSA Tests for Cancer and Benign
Prostatic Hyperplasia.**

Tuesday, July 26, 2:00 p.m. B-34

Ross J. Molinaro

**Identification of RNA Activators of 2',5'-
Oligoadenylate Synthetase in Prostate Cancer Cells**

Tuesday, July 26, 2:00 p.m. B-85

Dan Chen, PhD

**The Correlation of Hepatitis B(HB) viral DNA
in HBsAg Weakly Positive Samples by the
Immulite 2000 Assay**

Tuesday, July 26, 2:00 p.m. B-123

Gausai A. Khan

**Isolation and Characterization of a Novel
Protein from Goat Kidney and its Involvement
in Nitric Oxide Production**

Tuesday, July 26, 2:00 p.m. B-131

Michael N. Fahie-Wilson

**Macro Creatine Kinase (MacroCK):
Should We Be Screening for It?**

Wednesday, July 27, 10:00 a.m. C-7

Mohamed Allam, MD, PhD

**The Hypotensive Effect of Isoflurane Might be
Related to Increased Production of Nitric Oxide**

Wednesday, July 27, 10:00 a.m. C-8

Mohamed Allam, MD, PhD

**Up Regulation of Angiogenic Growth Factors
is Associated with Renal Dysfunction
in Type 2 Diabetes Mellitus**

Wednesday, July 27, 10:00 a.m. C-9

Mohamed Allam, MD, PhD

**Impact of Renal Functional Impairment
on Serum Tumor Markers Levels**

Advancing Scholarship in Laboratory Medicine

Wednesday, July 27, 10:00 a.m. C-30

Mustafa Serteser

Carbohydrate-Deficient Transferrin Levels in Non-Alcoholic Psychiatric Patients: Could It Be Used to Discriminate Psychiatric Disorders?

Wednesday, July 27, 10:00 a.m. C-56

Peter I. Kupchak, PhD

Clinical Utility of Highly Sensitive Assays for Biochemical Markers of Traumatic Brain Injury in the Emergency Department: A Prospective Case-Control Study

Wednesday, July 27, 10:00 a.m. C-60

Christa M. Cobbaert, PhD

Significance of *HFE* (C282Y, H63D) and *FPN1* (N144H) Gene Mutations in the Development of Cardiovascular Disease. Results from the Dutch Prospective Monitoring Project on Cardiovascular Disease Risk Factors.

Wednesday, July 27, 10:00 a.m. C-66

Anthony P. Furnary

The Portland Diabetic Project: Correcting the Unfair Disadvantage for Diabetic Patients Undergoing Cardiac Surgery

Wednesday, July 27, 10:00 a.m. C-87

Scott J. Cameron, PhD

A Novel Atheroprotective Mechanism for High Density Lipoprotein: Attenuation of Endothelial Cell Inflammation.

Wednesday, July 28, 10:00 a.m. C-143

Douglas F. Stickle, PhD

Evaluation of Effects of Varying Hematocrit on Injected Mass of Internal Standard in Immunosuppressants Measurement by Tandem Mass Spectrometry

Wednesday, July 27, 10:00 a.m. C-150

Alejandro R. Molinelli

Increased Hydrogen Peroxide-Induced DNA Strand Breaks by Arsenic Compounds in Human Cells

Wednesday, July 27, 10:00 a.m. C-158

Marjorie Bon Homme

Potential Role for IFN- γ and IL-6 in Mediating Adaptive Tolerance to Acute Acetaminophen Toxicity

Wednesday, July 27, 2:00 p.m. D-87

Dr. Christian Götting

Detection of Novel ABCC6 Sequence Variations in Pseudoxanthoma Elasticum Patients from German Descent

Wednesday, July 27, 2:00 p.m. D-125

Dean W. Joelson

Rarity of Folate Deficiency Suggests Limited Clinical Utility of Routine Folate Testing

Thursday, July 28, 10:00 a.m. E-31

Leslie Holland

The Role of Automation in Reducing Test Turnaround Time Outliers and Decreasing Patient Length of Stay in the Emergency Department

Thursday, July 29, 10:00 a.m. E-125

Hassan M. Hussien Qazzaz, PhD

Evidence that DLIF and OLF have Different Biosynthetic Pathways in Adrenal Cells: A Potential New Model for Steroidogenesis in Adrenal Cells

Thursday, July 28, 10:00 a.m. E-144

Mark D. Shephard

Point-of-Care HbA1c and Urine ACR Testing for Diabetes Management in Rural and Remote Australian Aboriginal Medical Services - the 'QAAMS' Program Sets an International Precedent



Advancing Scholarship in Laboratory Medicine

THE ACADEMY EXTENDS ITS APPRECIATION
TO THE FOLLOWING NACB FELLOWS
WHO PARTICIPATED AS DISTINGUISHED ABSTRACT
REVIEWERS DURING 2004 AND 2005:

KHOSROW ADELI
THOMAS ANNESLEY
DANIEL BANKSON
ROGER BERTHOLF
MICHAEL BISSELL
LARRY BOND
LARRY BROUSSARD
ANTHONY BUTCH
DENNIS DIETZEN
ELIZABETH FRANK
ALBERT FRASER
CATHERINE HAMMETT-STABLER
PATRICIA JONES
ANTHONY KILLEEN
LORALIE LANGMAN
STANLEY LO
GREG MAKOWSKI
ROBERTA REED
WILLIAM ROBERTS
FRANK SEDOR
SALVADOR SENA
DAVID WELLS
WILLIAM WINTER

Topic and Speaker Schedule

Edutrak Session 3401
National Academy of Clinical Biochemistry
Laboratory Medicine Practice Guidelines
Guidelines for the Use of Tumor Markers in the Clinic
Wednesday July 27, 2005
Orange County Convention Center—Room 304 E-H

MORNING SESSION: 10:30 AM – 12:00 NOON 10:30 – 11:10

Welcome and Introduction – *E. Diamandis*
Quality Requirements and Control – *C. Sturgeon*
Strategies Used to Develop
Practice Guidelines – *B. Hoffman*

11:15-Noon

Presentations of Guideline Recommendations
followed by Public Comment and Discussion
(*Discussant*)

Breast cancer (*M. Duffy*); **Plasma cell dyscrasias
(monoclonal gammopathies)** (*M. Fleisher*);
Gastric cancer (*J. Bonfrer*); **Liver cancer** (*C.
Sturgeon*); **Lung cancer** (*E. Diamandis*)

AFTERNOON SESSION: 2:45 PM – 5:00 PM

2:45-3:30 PM

Presentations of Guideline Recommendations fol-
lowed by Public Comment and Discussion
(*Discussant*)

Prostate cancer (*L. Sokoll*); **Ovarian cancer**
(*D. Chan*); **Cervical cancer** (*J. Bonfrer*); **Tumors
of testicular/germ cell origins** (*U-H. Stenman*);
Bladder cancer (*E. Diamandis / B. Hoffman*)

3:35-4:20 PM

Presentations of Guideline Recommendations
followed by Public Comment and Discussion
(*Discussant*)

Pancreatic cancer (*E. Diamandis / B. Hoffman*);
Parathyroid cancers (*J. Wu*); **Neuroendocrine
tumors** (*pheochromocytoma, neuroblastoma, carci-
noid tumors*) (*E. Diamandis / B. Hoffman*); **Skin
cancer (melanoma)** (*R. Gupta*); **Colorectal cancer**
(*J. Duffy*)

4:25-5:00 PM

Presentations of Guideline Recommendations
followed by Public Comment and Discussion
(*Discussant*)

Thyroid cancer (*R. Whitley*); **Recommendations
regarding the use of Microarrays** (*E-D. van der
Merwe*) and **Mass Spectrometry** (*D. Chan*)
Concluding remarks (*E. Diamandis*)

Drafts of the 2005 revisions to the **Tumor Marker
Laboratory Medicine Practice Guidelines** may be
previewed at www.nacb.org.

2005 NACB MEMBERSHIP COMMITTEE REPORT

The final NACB membership numbers for 2004 along with the current 2005 membership numbers are given below. As shown the 2004 figures indicate that NACB membership has decreased slightly over 2003. Renewal notices have been sent to members who have not sent in their 2004 dues. All Fellows that have joined since the last annual meeting are to be recognized at the annual Awards Luncheon and membership meeting at the IFCC/AACC Meeting in Orlando, Florida.

In February a letter co-signed by NACB President Dr. Mary Burritt and AACC President Dr. Mitch Scott was sent to 146 individuals in the UK, Ireland, New Zealand, and Australia inviting them to consider applying for membership in the NACB. Since the letter was sent 11 new international members have been approved.

NACB	Oct. '99	Oct. '00	Oct. '01	Oct. '02	Oct. '03	Oct. '04	Oct. '05
Fellow	290	367	427	423	438	432	429
Associate fellow	7	6	7	15	15	13	21
Emeritus fellow	76	66	78	82	82	86	84
Honorary fellow*	8	8	8	2	1	1	1
Total	381	447	520	522	536	532	535
Percent renewal						95.1%	94.9%
* as of 5/1/02 only honorary fellows with contact information included							
New Fellows		92	80	23	28	19	17
New Associate Fellows		1	1	9	3	1	8

2006 Beckman Conference

Gary Myers, PhD announces the members of the LMPG Committee developing guidelines regarding Emerging Risk Factors of Long Term Risk Stratification: Robert Christenson (co-chair), Christie Ballantyne, Gerald R. Cooper, Mary Cushman, Scott Grundy, Darwin Labarthe, Daniel Levy, Gary L Myers, Nader Rifai, and Peter Wilson. The recommendations developed by this committee will be presented during the 2006 Beckman Conference (October 2006). To keep the conference and guidelines focused the committee will focus on Inflammatory markers, Lipoproteins (to include Lp(a), Apo AI & B, and LDL subclasses and particle concentration, BNP, Renal Markers, and Homocysteine.

LabTests Online Reaches Milestone

NACB is a sponsor of LabTests Online. One year after hosting its 5 millionth visitor in February, 2004, Lab Tests Online has hosted its 10 millionth and was recognized in the Medicine on the Net Web Excellence Awards for Outstanding Content among Consumer Portals. It received an honorable mention in the content category.

Coming Soon: the CD Version of the Emergency Toxicology LMPG

In the next few weeks, a CD containing a revision of the Emergency Toxicology monograph will be mailed to NACB Fellows. Based on survey results, a CD version was determined to be the most economical and favored medium to distribution of the monograph.